INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Inhibrx Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$89.79−0.04 (-0.04%)
Close on Oct 19, 2026
- Market cap
- $1.41B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Operating margin
-10386.5%−9863.2 pts over 5 years
Net margin
-10773.5%−10182.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +550.0% | -16.0% | -36.8% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 841.3% | -197.8% | |
| Return on assets | – | -89.4% | -85.6% | |
| Current ratio | – | 4.21 | 3.93 | |
| Debt to equity | – | – | 12.58 | |
| Net debt to EBITDA | – | – | 0.18× | |
| Interest coverage | – | – | -11.1× | |
| Capex to revenue | – | 10.6% | 2.4% | |
| Diluted shares | – | 6M | 15M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Inhibrx Biosciences generated $713.14M from operations and spent $8.77M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$713.14M
Used
$8.77M
Capital expenditure$8.77M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-10773.5%
×Asset turnover0.01×
×Equity multiplier2.31×
=Return on equity, FY2025-197.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -10773.5% | 0.01× | 2.31× | -197.8% |
| FY2024 | 843786.0% | 0.00× | 2.76× | 1905.9% |
| FY2023 | -13408.9% | 0.01× | 5.90× | -475.3% |
| FY2022 | -6625.3% | 0.01× | 4.00× | -263.0% |
| FY2021 | -1130.8% | 0.05× | 2.30× | -127.9% |
| FY2020 | -590.7% | 0.15× | -9.41× | 841.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$140.06M
- Cash generatingOperating cash flow above zero-$129.79M
- Return on assets improvedROA up on the prior year548.1% → -77.5%
- Earnings backed by cashOperating cash flow above net income-$129.79M vs -$140.06M
- Less leverageLong-term debt to assets fell0.0% → 68.7%
- Better liquidityCurrent ratio rose3.94 → 3.93
- No dilutionShare count did not rise15M → 15M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.01